Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Goserelin - AstraZeneca

Drug Profile

Goserelin - AstraZeneca

Alternative Names: Goserelin acetate implant; ZD-9393; Zoladex

Latest Information Update: 04 Jun 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; TerSera Therapeutics
  • Class Antineoplastics; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer; Endometriosis; Prostate cancer; Uterine haemorrhage
  • Phase II Salivary gland cancer

Most Recent Events

  • 03 Jun 2022 Efficacy and adverse events data from phase II trial in Salivary gland cancer presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
  • 26 Apr 2022 Goserelin is still in phase II trials for Salivary gland cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in USA (SC) (NCT03942653)
  • 10 May 2021 AstraZeneca withdraws a phase III LARES trial for Breast Cancer (Early stage disease), prior to enrolment initiation, as the investigators trying RWS pathway for the indication expend, in China (NCT03658213)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top